BRAF and melanoma: We show that most combinatorial dose regimens achievable in the clinic are effective for treating BRAF mutant melanoma thanks to the higher single-agent potency and drug additivity, whereas NRAS mutant melanoma requires more precise dosing to harness drug synergy, posing practical implementation challenges due to interpatient pharmacokinetic variability.